J Rodon

Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors.

J. Baselga, G. Shapiro, E. Kwak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

A. Iafrate, E. Felip, J. Tabernero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.

Yuan Qi, G. Mills, Y. Qi, 2019, JCO precision oncology.

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

R. Schilsky, J. Lee, R. Berger, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.